Key result
Each 1-point increase in CHA2DS2-VASc score in diabetic patients without AF increased the risk of stroke (aHR 1.43; 95% CI 1.14-1.79), coronary events (aHR 1.55), and death (aHR 1.94).
Why the study?
Risk factors in the CHA2DS2-VASc score may predispose to cardiovascular events regardless of AF presence, prompting exploration of its predictive value in diabetic patients without AF.
Does the CHA2DS2-VASc score predict cardiovascular events and death in diabetic patients without atrial fibrillation?
Cohort (n=610)
Does the CHA2DS2-VASc score predict cardiovascular events and death in diabetic patients without atrial fibrillation?
Hazard Ratio: 1.43 (95% CI 1.14–1.79)
p-value: p=0.001
The CHA2DS2-VASc score is an independent predictor of ischemic stroke, coronary events, and overall mortality in diabetic patients without atrial fibrillation.
Supports CHA2DS2-VASc for risk stratification in diabetes without AF; leaves open whether score-guided interventions improve outcomes.
Background Risk factors included in the cardiovascular (CHA2DS2‐VASc) score, currently used for atrial fibrillation (AF), may predispose to cardiovascular events whether or not AF is present. The aim was to explore the predictive role of CHA2DS2‐VASc score on cardiovascular outcomes in diabetic patients without AF. Methods We accessed individual data from 610 diabetic patients without AF at baseline included in the prospective cohort of the Malmö Diet and Cancer study. Main outcome measure was the occurrence of cardiovascular events (stroke, coronary events) and death. Mean follow‐up was 14.5 ± 5 years (8845 person/years). Results The CHA2DS2‐VASc score significantly predicted the risk of all outcome measures. There was a significant increase in stroke, coronary events, and death risk by each point of CHA2DS2‐VASc score elevation [stroke: adjusted hazard ratio (aHR) 1.43, 95% CI 1.14‐1.79, P = 0.001; coronary events: aHR 1.55, 95% CI 1.34‐1.80, P < 0.0001; death: aHR 1.94, 95% CI 1.71‐2.21, P < 0.0001]. A CHA2DS2‐VASc score ≥4 was associated with higher incidence of ischemic stroke (aHR 1.47, 95% CI 1.18‐1.82; P = 0.001), coronary events (aHR 1.32; 95% CI 1.11‐1.58; P = 0.002), and death (aHR 1.36; 95% CI 1.20‐1.54; P < 0.001). Conclusions In this population‐based study on diabetic patients without AF, the CHA2DS2‐VASc score was an independent predictor of ischemic stroke, coronary events, and overall mortality. Regardless of the AF status, the CHA2DS2‐VASc score might represent a rapid and user‐friendly tool for clinical assessment of diabetic patients at higher cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Patti et al. (2019) conducted a cohort in Diabetes without atrial fibrillation (n=610). CHA2DS2-VASc score was evaluated on Stroke (per point increase in CHA2DS2-VASc score) (aHR 1.43, 95% CI 1.14-1.79, p=0.001). Each 1-point increase in CHA2DS2-VASc score in diabetic patients without AF increased the risk of stroke (aHR 1.43; 95% CI 1.14-1.79), coronary events (aHR 1.55), and death (aHR 1.94).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: